Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Merck (NYSE:MRK) said on Thursday that its investigational coformulation for metastatic non-small cell lung cancer (NSCLC) did not show an improvement in median progression-free survival (PFS ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024 ...

From the late 1950s to early 1980s, for example, Merck medical scientist Dr. Maurice Hilleman ... Merck regional hub in South San Francisco, home to the world’s largest biotech cluster, with ...

Merck operates in the medical sector and competes with big pharma companies like Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Co. (NYSE: BMY), and Eli Lilly and Co. (NYSE: LLY). Merck's top ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Merck broke down the results Friday at the European Society of Medical Oncology Congress in Barcelona. In an email, the company pointed out that the majority of patients in LITESPARK-005 received ...

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...